Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for GVHD Prevention in Allogeneic Transplant
NCT01790568Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Started Dec 2014; status: completed.
02
Drugs
vorinostat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01790568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01790568.